BioWorld

July 31, 2006

View Archived Issues

MyVax Misses Statistical Hurdle, Genitope Plunges

In a disappointing case of déj vu, investors drove down shares in Genitope Corp. by 48.6 percent after learning that a Phase III study of its lead cancer treatment would last longer than expected. (BioWorld Today) Read More

Sales Force Layoff 'Neutral' As Neurocrine Marches On

Read More

Radiation-Killed Bacteria Can Elicit T-Cell Immune Response

Read More

As The BioWorld Turns: From White Biotech To Stem Cell Fun

Read More

Cangene Gets $143M HHS Contract For Anthrax Drug

Read More

Other News To Note

Read More